10x Genomics (TXG) EBT Margin (2018 - 2026)

10x Genomics has disclosed EBT Margin across 9 years of filings, most recently posting 8.52% for Q1 2026.

• EBT Margin for Q1 2026 came in at 8.52%, up 1312.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 3.01% (up 2154.0% YoY), and the FY2025 annual result was 6.21%, up 2289.0% from the prior year.
• EBT Margin came in at 8.52% for Q1 2026 at 10x Genomics, up from 9.15% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 21.4% in Q2 2025 to a low of 59.71% in Q3 2023.
• The 5-year median for EBT Margin is 25.33% (2023), against an average of 26.51%.
• Across the five-year window, EBT Margin sank 4710 bps in 2022 and surged 4562 bps in 2025, its largest moves.
• 10x Genomics' EBT Margin stood at 10.5% in 2022, then plunged by 141 bps to 25.33% in 2023, then declined by 16 bps to 29.32% in 2024, then jumped by 69 bps to 9.15% in 2025, then grew by 7 bps to 8.52% in 2026.
• The last three EBT Margin figures came in at 8.52% (Q1 2026), 9.15% (Q4 2025), and 18.93% (Q3 2025), per Business Quant data.